172 related articles for article (PubMed ID: 16334552)
1. [Constructing recombinant plasmid with prostate-specific membrane antigen promoter and reverse enhancer and comparing the transcription activity of enhancers in different directions].
Zeng H; Liao YC; Wang F; Wu Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Nov; 36(6):782-5. PubMed ID: 16334552
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
3. [The construction of recombinant plasmid with prostate-specific membrane antigen promoter controlling reporter gene expression].
Zeng H; Li H; Liao YC; Li X; Wu Q; Yang YR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):169-71. PubMed ID: 15807257
[TBL] [Abstract][Full Text] [Related]
4. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
5. [Establishment of RNA interfering retrovirus vector targeting CXCR4 gene driven by human prostate-specific antigen promoter and its biological effects on prostate cancer cells].
Du YF; Xing YF; Zeng FQ; Lu P; Liu XY; Xiao YJ
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):489-94. PubMed ID: 18069626
[TBL] [Abstract][Full Text] [Related]
6. Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.
Zeng H; Wu Q; Li H; Wei Q; Lu Y; Li X; Wang F; Zhao F; Ding Z; Yang Y
J Androl; 2005; 26(2):215-21. PubMed ID: 15713827
[TBL] [Abstract][Full Text] [Related]
7. [Construction and expression of recombinant plasmid with prostate-specific membrane antigen promoter and enhancer regulating uracil phosphoribosyltransferase gene].
Zhao FJ; Li H; Cheng HM; Zeng H; Wei Q; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):172-5. PubMed ID: 15807258
[TBL] [Abstract][Full Text] [Related]
8. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
[TBL] [Abstract][Full Text] [Related]
9. Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.
Chapel-Fernandes S; Jordier F; Lauro F; Maitland N; Chiaroni J; de Micco P; Mannoni P; Bagnis C
Cancer Gene Ther; 2006 Oct; 13(10):919-29. PubMed ID: 16741521
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
11. [Construction and targeting study of eukaryotic expression vector modulated by a macrophage-specific promoter].
Wen YA; Guo JY; Yu XL; Cen D; Liu JB; Chen Y; Zhang J; Tu ZG
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 May; 24(5):441-3. PubMed ID: 18466696
[TBL] [Abstract][Full Text] [Related]
12. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Yu DC; Sakamoto GT; Henderson DR
Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
[TBL] [Abstract][Full Text] [Related]
13. [Construction and identification of a plasmid with EGFP reporter gene for enhancer function analysis].
Shi QD; Zhang PB; Kang QY; Chen XL; Tian YM; Liu JX; Liu Y
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1834-7. PubMed ID: 18158996
[TBL] [Abstract][Full Text] [Related]
14. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
15. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.
Pang S; Dannull J; Kaboo R; Xie Y; Tso CL; Michel K; deKernion JB; Belldegrun AS
Cancer Res; 1997 Feb; 57(3):495-9. PubMed ID: 9012480
[TBL] [Abstract][Full Text] [Related]
16. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Majumdar S; Diamandis EP
Br J Cancer; 1999 Mar; 79(9-10):1594-602. PubMed ID: 10188912
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific expression detected with the use of an expression vector driven by human telomerase reverse transcriptase gene promoter.
Yin J; Fu P; Wang X; Jin G; Xiu R
J Lab Clin Med; 2004 Dec; 144(6):302-6. PubMed ID: 15614252
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
Lee CH; Liu M; Sie KL; Lee MS
Anticancer Res; 1996; 16(4A):1805-11. PubMed ID: 8712704
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer.
Noss KR; Wolfe SA; Grimes SR
Gene; 2002 Feb; 285(1-2):247-56. PubMed ID: 12039052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
